Oncology Institute Inc (TOI) - Total Assets
Based on the latest financial reports, Oncology Institute Inc (TOI) holds total assets worth $168.23 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Oncology Institute Inc cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Oncology Institute Inc - Total Assets Trend (2019–2025)
This chart illustrates how Oncology Institute Inc's total assets have evolved over time, based on quarterly financial data. See what is Oncology Institute Inc's book value for net asset value and shareholders' equity analysis.
Oncology Institute Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Oncology Institute Inc's total assets of $168.23 Million consist of 68.5% current assets and 31.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 20.4% |
| Accounts Receivable | $59.32 Million | 36.0% |
| Inventory | $16.88 Million | 10.3% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $11.02 Million | 6.7% |
| Goodwill | $7.23 Million | 4.4% |
Asset Composition Trend (2019–2025)
This chart illustrates how Oncology Institute Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Oncology Institute Inc.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Oncology Institute Inc's current assets represent 68.5% of total assets in 2025, an increase from 36.6% in 2019.
- Cash Position: Cash and equivalents constituted 20.4% of total assets in 2025, up from 4.1% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 10.0% of total assets, a decrease from 59.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 36.0% of total assets.
Oncology Institute Inc Competitors by Total Assets
Key competitors of Oncology Institute Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fresenius SE & Co. KGaA
XETRA:FRE
|
Germany | €42.46 Billion |
|
Apollo Hospitals Enterprise Limited
NSE:APOLLOHOSP
|
India | Rs219.50 Billion |
|
Sienna Senior Living Inc
TO:SIA
|
Canada | CA$2.35 Billion |
|
Mitra Keluarga Karyasehat Tbk PT
JK:MIKA
|
Indonesia | Rp9.64 Trillion |
|
Chularat Hospital Public Company Limited
BK:CHG
|
Thailand | ฿10.61 Billion |
|
Hospital Mater Dei S.A
SA:MATD3
|
Brazil | R$4.33 Billion |
|
Lippo Karawaci Tbk
JK:LPKR
|
Indonesia | Rp48.70 Trillion |
|
ARRAIL GROUP LTD.
F:I1D
|
Germany | €3.16 Billion |
Oncology Institute Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.47 | 1.79 | 1.76 |
| Quick Ratio | 1.17 | 1.59 | 1.59 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $37.51 Million | $47.28 Million | $20.87 Million |
Oncology Institute Inc - Advanced Valuation Insights
This section examines the relationship between Oncology Institute Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.76 |
| Latest Market Cap to Assets Ratio | 2.43 |
| Asset Growth Rate (YoY) | -4.7% |
| Total Assets | $164.66 Million |
| Market Capitalization | $400.93 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Oncology Institute Inc's assets at a significant premium (2.43x), suggesting investors see substantial growth potential or unique competitive advantages.
Slight Asset Contraction: Oncology Institute Inc's assets decreased by 4.7% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Oncology Institute Inc (2019–2025)
The table below shows the annual total assets of Oncology Institute Inc from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $164.66 Million | -4.67% |
| 2024-12-31 | $172.72 Million | -17.46% |
| 2023-12-31 | $209.24 Million | -20.04% |
| 2022-12-31 | $261.67 Million | +28.62% |
| 2021-12-31 | $203.44 Million | +209.70% |
| 2020-12-31 | $65.69 Million | +10.36% |
| 2019-12-31 | $59.52 Million | -- |
About Oncology Institute Inc
The Oncology Institute, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company offers physician services, in-house infusion, in-house specialty pharmacy, clinical trials, radiation therapy, and outpatient blood product transfusion services, as well as edu… Read more